I’m joined by Dr. Paul Song, Chairman & CEO of NKGen Biotech.
Paul has led across biotech, from CMO at NKGEN to co-founding Fuse Biotherapeutics and since 2022 he’s been driving NKGen’s mission to harness natural killer cells through their proprietary SNK platform for neurodegenerative diseases and cancer.
In this episode, we dive into his decision to return and lead NKGen, the science behind the SNK platform, the company’s recent SPAC merger and NASDAQ listing, and his perspective on building resilient biotech companies in today’s market.Enjoy and stay tuned.
